Sacituzumab Govitecan Yields Significant OS Improvement Vs Physician's Choice in HR+/HER2– Metastatic Breast Cancer - Cancer Network

Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s c…

A statistically significant and clinically meaningful improvement in overall survival (OS) was observed following treatment with sacituzumab govitecan-hziy (Trodelvy) for patients with hormone recept… [+4855 chars]

full article...